CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6 enrolled
Drug / intervention
Alfentanildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01008059
NCT01008059N/ACompleted
CompareCT.gov

Novel Noninvasive Assessment of Cytochrome P4450 Activity: Simultaneous Testing Pilot

Washington University School of Medicine·interventional·Posted Nov 5, 2009·Updated May 17, 2019

In Brief

A clinical study evaluating Alfentanil for Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A. Completed, enrolled 6 participants across 1 site.

Detailed Summary

To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A activity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEvaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A
CountriesUnited States
CollaboratorsNational Institute of General Medical Sciences (NIGMS)

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 5, 2009
Enrollment StartOct 1, 2009
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 16.7 years ago

Interventions

Alfentanildrug

No drug treatment before alfentanil